Intracellular Th (ITCI NASDAQ) stock market data APIs
$131.6942
-0.49(-0.4%)
as of April 1, 2025
Intracellular Th Financial Data Overview
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Prev. Close
131.6942
Open
131.2053
High
132.6381
Low
132.0915
52 wk Range
64.09-131.98
Market Cap
14 047 M
Shares Outstanding
107 M
Revenue
681 M
EPS
-0.16
Beta
0.462
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Intracellular Th data using free add-ons & libraries
Get Intracellular Th Fundamental Data
Intracellular Th Fundamental data includes:
- Net Revenue: 681 M
- EBITDA: -116 213 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-20
- EPS/Forecast: -0.1109
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intracellular Th News
New
Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI)
Enable social media cookies to share Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) By Mill Chart Last update: Apr 8, 2025 Growth investors are looking for stocks show...
Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition
Johnson & Johnson (JNJ) expects its pending acquisition of Intra-Cellular Therapies (ITCI) to have a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 21.4% in that time frame, underperforming the S&P 500. Will the recent negative trend cont...
Is Intra-Cellular Therapies, Inc. (ITCI) a Best Biotech Stock According to Billionaires?
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands ag...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
